Renoprotective effects of topiroxostat for Hyperuricaemic patients with overt diabetic nephropathy study (ETUDE study): A prospective, randomized, multicentre clinical trial.

Toshihiro MizukoshiSawako KatoMasahiko AndoHiroshi SobajimaNorimi OhashiTomohiko NaruseYosuke SakaHideaki ShimizuTakanobu NagataShoichi Maruyama

Published in: Nephrology (Carlton, Vic.) (2019)

Topiroxostat 160 mg daily reduced albuminuria in patients with diabetic nephropathy. (Funded by Sanwa Kagaku Kenkyusho; Trial registration, UMIN000015403).

Keyphrases

diabetic nephropathy
clinical trial
study protocol
phase ii
phase iii